Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ1862MR)

This product GTTS-WQ1862MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001037631.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1493
UniProt ID	P16410

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1862MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11834MR	IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MK-4280
GTTS-WQ12942MR	IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	PankoMab
GTTS-WQ8177MR	IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HL161
GTTS-WQ9107MR	IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	IMGN242
GTTS-WQ14146MR	IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	aPCSK927
GTTS-WQ10242MR	IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	LFB-R603
GTTS-WQ6247MR	IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CR57
GTTS-WQ10812MR	IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	M7824

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST